Anthera Pharmaceuticals Inc. (ANTH)

Company Description

Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious illnesses, including cardiovascular and autoimmune diseases. Clinical-stage program includes a Phase 2, blisibimod study. Blisibimod targets elevated levels of B-lymphocyte stimulator, or BLyS (also known as BAFF), which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis, multiple sclerosis, Sjögren’s Syndrome, Graves’ Disease and others.

COMPANY ADDRESS
25801 Industrial Blvd.
Suite B
Hayward, CA 94545
United States

COMPANY PHONE
510-856-5600

COMPANY WEBSITE



Get BioInvest's perspective on Anthera's CEO


Latest Company News

Anthera Pharmaceuticals Announces RESULT Phase 3 Clinical Study of Sollpura ... GlobeNewswire (press release) - Aug 14, 2017 14, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals (Nasdaq:ANTH) today announced that the RESULT Phase 3 clinical study of Sollpura for exocrine pancreatic insufficiency due to cystic fibrosis has been approved by the European Cystic Fibrosis Society ... Anthera's late-stage study of Sollpura to be included in European CF network ... - Seeking Alpha [...]
Mon, Aug 14, 2017 12:22:00 PM, Continue reading at the source
Anthera Pharmaceuticals Provides Business Update and Reports 2017 Second ... GlobeNewswire (press release) - Aug 9, 2017 Anthera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing products to treat serious and life-threatening diseases, including exocrine pancreatic insufficiency and IgA nephropathy. [...]
Wed, Aug 09, 2017 12:22:00 PM, Continue reading at the source
Anthera Pharmaceuticals: A Series Of Unfortunate Events Seeking Alpha - Aug 8, 2017 Anthera Pharmaceuticals is a clinical-stage biopharma company developing innovative therapies to improve existing treatments and enable treatment for unmet medical needs. Anthera Pharmaceuticals Incorporated (NASDAQ:ANTH)'s Stock Is Buy After Less ... - BZ Weekly [...]
Tue, Aug 08, 2017 3:22:00 AM, Continue reading at the source
Anthera Pharmaceuticals Announces RESULT Phase 3 Clinical Study of Sollpura ... GlobeNewswire (press release) - Jul 10, 2017 HAYWARD, Calif., July 10, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals (Nasdaq:ANTH) today announced that the RESULT Phase 3 clinical study of Sollpura for exocrine pancreatic insufficiency due to cystic fibrosis has been approved by the Cystic ... Anthera Pharmaceuticals Inc (ANTH) Can't Burn Your Short Portfolio. Just ... - WeeklyHub Biotech Lows: Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH), Celsion Corporation ... - Benchmark Monitor [...]
Mon, Jul 10, 2017 12:33:00 PM, Continue reading at the source
Anthera Pharma to be 'opportunistic' with capital raising Seeking Alpha - Jun 16, 2017 Speaking to Bloomberg, Anthera Pharma (ANTH -2.1%) CEO Craig Thompson says there's no apparent reason for this week's rally (up more than 20% at one point). [...]
Fri, Jun 16, 2017 7:18:00 PM, Continue reading at the source
Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock and ... GlobeNewswire (press release) - Mar 13, 2017 HAYWARD, Calif., March 13, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) (the “Company”) today announced that it intends to offer and sell shares of its common stock and warrants to purchase shares of its common stock in an ... Anthera Pharmaceuticals (ANTH) Stock: Dives On Secondary Public Offering - CNA Finance (press release) [...]
Mon, Mar 13, 2017 7:52:00 PM, Continue reading at the source
Anthera Pharmaceuticals Provides Business Update and Reports 2016 Fourth ... GlobeNewswire (press release) - Feb 27, 2017 HAYWARD, Calif., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today provided a business update and reported financial results for the 2016 fourth quarter and the fiscal year ending December 31, 2016. [...]
Mon, Feb 27, 2017 9:00:00 PM, Continue reading at the source
Anthera Pharmaceuticals Now Trading Below Cash Value. This Biotech Could Rise ... Seeking Alpha - Feb 22, 2017 Because of this, I love buying beaten-down biotech stocks that still have lots of upside potential as well as very strong, cash-rich balance sheets. Anthera Pharmaceuticals Inc (NASDAQ:ANTH): Ignore The Lawsuits - Insider Financial [...]
Wed, Feb 22, 2017 5:57:00 PM, Continue reading at the source
Anthera Pharmaceuticals downgraded at SunTrust, price target slashed to $1 from $6 MarketWatch - Dec 29, 2016 Anthera Pharmaceuticals Inc. shares ANTH, -0.73% were downgraded to hold from buy by SunTrust Robinson Humphrey on Thursday, after the company said one of its drugs had come up short in a study. [...]
Thu, Dec 29, 2016 12:59:00 PM, Continue reading at the source
Anthera Pharma plunges 66% after missing target in study MarketWatch - Dec 27, 2016 Anthera Pharmaceuticals Inc. ANTH, -1.53% lost roughly two-thirds of its market value in late trading Tuesday after the company announced that one of its drugs had come up short in a study. [...]
Tue, Dec 27, 2016 9:45:00 PM, Continue reading at the source